Stockreport

Cue Biopharma Produces Immuno-STAT™ Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck

Cue Biopharma, Inc.  (CUE) 
US:NASDAQ Investor Relations: cuebiopharma.gcs-web.com/news-releases
PDF CAMBRIDGE, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to sele [Read more]